杜皮卢马布用于耐火性慢性鼻炎,用于带有多炎的异性粒状炎症
Roberto Padoan1, Federica Davanzo1, Luca Iorio1
1Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy.
Rheumatology (Oxford, England)
|October 16, 2024
概括
杜皮卢马布有效地治疗耐火性慢性鼻炎与鼻在埃索诺菲尔性粒状瘤与多炎患者,改善症状和生活质量. 需要对潜在的不良事件进行仔细监测.
科学领域:
- 免疫学 免疫学 免疫学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 类风湿病学 类风湿病学
背景情况:
- 带有多炎 (EGPA) 的异性粒状炎通常涉及具有鼻息肉 (CRSwNP) 的耐火性慢性鼻炎.
- 目前对EGPA相关的CRSwNP的治疗有局限性.
- 杜皮卢马布在严重的CRSwNP中表现有前途.
研究的目的:
- 评估dupilumab在EGPA患者中治疗耐火性CRSwNP的疗效和安全性.
- 评估患者报告结果和客观测量的改善.
主要方法:
- 对EGPA患者进行前性观察研究,患者有活跃的CRSwNP和稳定的血管炎.
- 评估包括临床,生物,鼻科评估,PROM和鼻腔细胞学.
- 由BVAS和前尼松剂量定义的响应标准.
主要成果:
- 83.3%的患者在12个月内达到完全反应.
- 鼻腔症状,PROM和生活质量的显著改善 (AAV-PRO得分).
- 鼻腔细胞学显示,乙氨基和中性粒细胞减少;44.4%的人经历了不良事件,包括高乙氨基.
结论:
- 杜皮卢马布在EGPA中对严重的,耐火的ENT表现有效.
- 它可以改善症状,减少炎症,提高生活质量.
- 仔细的患者选择和监测对于管理不良事件至关重要.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
Drugs Used in Lower Respiratory Disorders: Overview
356
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
356
Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


